- Life Sciences
The President & CEO of Genovis AB (publ.) (STO:GENO), Fredrik Olsson, Just Bought 1.4% More Shares
Even if it's not a huge purchase, we think it was good to see that Fredrik Olsson, the President & CEO of Genovis AB (publ.) (STO:GENO) recently shelled out kr118k to buy stock, at kr56.88 per share. Although the purchase is not a big one, increasing their shareholding by only 1.4%, it can be interpreted as a good sign.
See our latest analysis for Genovis AB (publ.)
The Last 12 Months Of Insider Transactions At Genovis AB (publ.)
In fact, the recent purchase by President & CEO Fredrik Olsson was not their only acquisition of Genovis AB (publ.) shares this year. Earlier in the year, they paid kr36.10 per share in a kr552k purchase. Although we like to see insider buying, we note that this large purchase was at significantly below the recent price of kr58.40. Because the shares were purchased at a lower price, this particular buy doesn't tell us much about how insiders feel about the current share price.
Genovis AB (publ.) insiders may have bought shares in the last year, but they didn't sell any. The average buy price was around kr41.64. We don't deny that it is nice to see insiders buying stock in the company. But we must note that the investments were made at well below today's share price. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
Genovis AB (publ.) is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.
Insider Ownership Of Genovis AB (publ.)
I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. It appears that Genovis AB (publ.) insiders own 16% of the company, worth about kr596m. While this is a strong but not outstanding level of insider ownership, it's enough to indicate some alignment between management and smaller shareholders.
What Might The Insider Transactions At Genovis AB (publ.) Tell Us?
It's certainly positive to see the recent insider purchases. And an analysis of the transactions over the last year also gives us confidence. Once you factor in the high insider ownership, it certainly seems like insiders are positive about Genovis AB (publ.). One for the watchlist, at least! So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. Every company has risks, and we've spotted 2 warning signs for Genovis AB (publ.) (of which 1 can't be ignored!) you should know about.
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.
Valuation is complex, but we're helping make it simple.
Find out whether Genovis AB (publ.) is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.View the Free Analysis
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Genovis AB (publ.)
Genovis AB (publ.) designs, develops, and sells tools for development of drugs for customers in the pharmaceutical and medical device industries.
Exceptional growth potential with flawless balance sheet.